ELAN
Price
$18.43
Change
+$0.96 (+5.50%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
9.16B
66 days until earnings call
TEVA
Price
$18.95
Change
+$0.46 (+2.49%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
21.43B
61 days until earnings call
Interact to see
Advertisement

ELAN vs TEVA

Header iconELAN vs TEVA Comparison
Open Charts ELAN vs TEVABanner chart's image
Elanco Animal Health
Price$18.43
Change+$0.96 (+5.50%)
Volume$51.28K
Capitalization9.16B
Teva Pharmaceutical Industries
Price$18.95
Change+$0.46 (+2.49%)
Volume$31.23K
Capitalization21.43B
ELAN vs TEVA Comparison Chart in %
Loading...
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ELAN vs. TEVA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ELAN is a Hold and TEVA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ELAN: $18.43 vs. TEVA: $18.95)
Brand notoriety: ELAN and TEVA are both notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ELAN: 91% vs. TEVA: 69%
Market capitalization -- ELAN: $9.16B vs. TEVA: $21.43B
ELAN [@Pharmaceuticals: Generic] is valued at $9.16B. TEVA’s [@Pharmaceuticals: Generic] market capitalization is $21.43B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.93B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ELAN’s FA Score shows that 0 FA rating(s) are green whileTEVA’s FA Score has 1 green FA rating(s).

  • ELAN’s FA Score: 0 green, 5 red.
  • TEVA’s FA Score: 1 green, 4 red.
According to our system of comparison, TEVA is a better buy in the long-term than ELAN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ELAN’s TA Score shows that 5 TA indicator(s) are bullish while TEVA’s TA Score has 7 bullish TA indicator(s).

  • ELAN’s TA Score: 5 bullish, 4 bearish.
  • TEVA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, TEVA is a better buy in the short-term than ELAN.

Price Growth

ELAN (@Pharmaceuticals: Generic) experienced а +0.44% price change this week, while TEVA (@Pharmaceuticals: Generic) price change was +3.10% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.08%. For the same industry, the average monthly price growth was +12.00%, and the average quarterly price growth was +86.48%.

Reported Earning Dates

ELAN is expected to report earnings on Nov 11, 2025.

TEVA is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+0.08% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
TEVA($21.4B) has a higher market cap than ELAN($9.16B). ELAN YTD gains are higher at: 44.261 vs. TEVA (-16.152). TEVA has higher annual earnings (EBITDA): 1.9B vs. ELAN (1.45B). TEVA has more cash in the bank: 2.16B vs. ELAN (539M). ELAN has less debt than TEVA: ELAN (4.21B) vs TEVA (17.5B). TEVA has higher revenues than ELAN: TEVA (16.6B) vs ELAN (4.48B).
ELANTEVAELAN / TEVA
Capitalization9.16B21.4B43%
EBITDA1.45B1.9B76%
Gain YTD44.261-16.152-274%
P/E Ratio20.94N/A-
Revenue4.48B16.6B27%
Total Cash539M2.16B25%
Total Debt4.21B17.5B24%
FUNDAMENTALS RATINGS
ELAN vs TEVA: Fundamental Ratings
ELAN
TEVA
OUTLOOK RATING
1..100
5626
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10059
SMR RATING
1..100
7993
PRICE GROWTH RATING
1..100
3945
P/E GROWTH RATING
1..100
9312
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TEVA's Valuation (75) in the Pharmaceuticals Generic industry is in the same range as ELAN (93) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew similarly to ELAN’s over the last 12 months.

TEVA's Profit vs Risk Rating (59) in the Pharmaceuticals Generic industry is somewhat better than the same rating for ELAN (100) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew somewhat faster than ELAN’s over the last 12 months.

ELAN's SMR Rating (79) in the Agricultural Commodities Or Milling industry is in the same range as TEVA (93) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew similarly to TEVA’s over the last 12 months.

ELAN's Price Growth Rating (39) in the Agricultural Commodities Or Milling industry is in the same range as TEVA (45) in the Pharmaceuticals Generic industry. This means that ELAN’s stock grew similarly to TEVA’s over the last 12 months.

TEVA's P/E Growth Rating (12) in the Pharmaceuticals Generic industry is significantly better than the same rating for ELAN (93) in the Agricultural Commodities Or Milling industry. This means that TEVA’s stock grew significantly faster than ELAN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ELANTEVA
RSI
ODDS (%)
Bearish Trend 2 days ago
74%
Bearish Trend 2 days ago
64%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
63%
Bearish Trend 2 days ago
73%
Momentum
ODDS (%)
Bullish Trend 2 days ago
55%
Bullish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
79%
Bullish Trend 2 days ago
68%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
75%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
65%
Bullish Trend 2 days ago
68%
Advances
ODDS (%)
Bullish Trend 10 days ago
62%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 3 days ago
74%
Bearish Trend 9 days ago
72%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
71%
Bullish Trend 4 days ago
78%
Aroon
ODDS (%)
Bullish Trend 2 days ago
70%
Bullish Trend 2 days ago
71%
View a ticker or compare two or three
Interact to see
Advertisement
ELAN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
TEVA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AGIX33.830.15
+0.45%
KraneShares Artfcl Intllgnc and Tech ETF
PSF20.390.01
+0.02%
COHEN & STEERS SELECT PREFERRED AND Income FUND
CMCI25.66N/A
N/A
VanEck® CMCI Commodity Strategy ETF
IAUM35.40-0.14
-0.39%
iShares® Gold Trust Micro
KGRN28.18-0.47
-1.64%
KraneShares MSCI China Clean Tech ETF

ELAN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ELAN has been loosely correlated with VTRS. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ELAN jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ELAN
1D Price
Change %
ELAN100%
+0.69%
VTRS - ELAN
54%
Loosely correlated
-2.09%
ZTS - ELAN
46%
Loosely correlated
+0.51%
EBS - ELAN
39%
Loosely correlated
-2.55%
PAHC - ELAN
37%
Loosely correlated
+2.29%
TLRY - ELAN
35%
Loosely correlated
-2.95%
More

TEVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, TEVA has been loosely correlated with AMRX. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if TEVA jumps, then AMRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To TEVA
1D Price
Change %
TEVA100%
-1.49%
AMRX - TEVA
40%
Loosely correlated
+0.10%
VTRS - TEVA
31%
Poorly correlated
-2.09%
ELAN - TEVA
30%
Poorly correlated
+0.69%
AQST - TEVA
26%
Poorly correlated
+28.10%
ESPR - TEVA
24%
Poorly correlated
+4.12%
More